F D C Ltd
NSE:FDC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
F D C Ltd
Revenue
F D C Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F D C Ltd
NSE:FDC
|
Revenue
₹20.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹346.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹283.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹568.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Revenue
₹261.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹127.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
F D C Ltd
Glance View
FDC Ltd. engages in the business of pharmaceutical. The company is headquartered in Mumbai, Maharashtra. The firm manufactures and distributes its range of generics, formulations and active pharmaceuticals at its manufacturing plants. The company also manufactures oral rehydration salts (ORS) and specialized formulations. The company has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. The company has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
See Also
What is F D C Ltd's Revenue?
Revenue
20.8B
INR
Based on the financial report for Dec 31, 2025, F D C Ltd's Revenue amounts to 20.8B INR.
What is F D C Ltd's Revenue growth rate?
Revenue CAGR 5Y
9%
Over the last year, the Revenue growth was 0%. The average annual Revenue growth rates for F D C Ltd have been 7% over the past three years , 9% over the past five years .